Mergers & Acquisitions - Biotechnology, Rare diseases

Filter

Popular Filters

Baxter buys AesRx, gaining rights to investigational SCD drug

Baxter buys AesRx, gaining rights to investigational SCD drug

10-07-2014

US drugmaker Baxter International said yesterday that it has acquired AesRx, a private US biopharmaceutical…

Aes-103AesRxBaxter InternationalBiotechnologyHematologyMergers & AcquisitionsRare diseasesUSA

Genzyme to gain rights to certain Alnylam rare disease pipeline products

Genzyme to gain rights to certain Alnylam rare disease pipeline products

13-01-2014

French drug major Sanofi’s US biotech subsidiary Genzyme and Alnylam Pharmaceuticals have significantly…

Alnylam PharmaceuticalsBiotechnologyGenzymeLicensingMergers & AcquisitionspatisiranRare diseasesResearchSanofi

Big news day for Amicus, with change in GSK deal, an acquisition and restructuring

Big news day for Amicus, with change in GSK deal, an acquisition and restructuring

22-11-2013

US biotech firm Amicus Therapeutics saw its shares fall 4.2% to $2.03 by mid-morning trading on Thursday,…

Amicus TherapeuticsBiotechnologyCallidus BiopharmaFinancialGlaxoSmithKlineLicensingManagementMergers & AcquisitionsmigalastatRare diseases

Chiesi expands rare disease portfolio with acquisition

26-08-2013

Privately-owned Italian drugmaker Chiesi Group has signed, through its UK affiliate, a definitive agreement…

BiotechnologyChiesi FarmaceuticiLamazymMergers & AcquisitionsPharmaceuticalRare diseasesZymenex

Shire acquires Premacure to expand in new therapy area

13-03-2013

In a second acquisition so far this year, Ireland-headquartered drugmaker Shire (LSE: SHP) said on Tuesday…

BiotechnologyMergers & AcquisitionsOphthalmicsPharmaceuticalPremacureRare diseasesShire

Shire to acquire Lotus Tissue Repair for undisclosed price

09-01-2013

Ireland-headquartered drugmaker Shire (LSE: SHP) said yesterday that it has signed an agreement to acquire…

BiotechnologyLotus Tissue RepairMergers & AcquisitionsPharmaceuticalRare diseasesShire

Pharming considers options, including a sale of the company

13-06-2012

Netherland-based biotech company Pharming Group (NYSE Euronext: PHARM) yesterday revealed that it is…

BiotechnologyLicensingMergers & AcquisitionsPharmingRare diseasesResearchRuconest

Actelion pulls out of Trophos option

13-12-2011

Switzerland-based Actelion (SIX: ATLN), Europe’s biggest biotech company, says that it has decided…

ActelionBiotechnologyLicensingMergers & AcquisitionsolesoximePharmaceuticalRare diseasesTrophos

Parexel

Parexel

Back to top